The antioxidant ubinon-9 was tested for its effects on platelet and plasma lipid peroxidation parameters in patients with acute ischemic heart diseases. The use of ubinon-9 in the multimodality therapy of patients with ischemic heart disease was shown to result in a significant decrease in lipid peroxidation intensity by enhancing superoxide dismutase activity in the platelets and plasma from the patients. Ubinon-9 equally prevented lipid peroxidation activation during enzymatic and nonenzymatic induction in the platelets of patients with unstable angina or acute myocardial infarction. Unlike a daily dose of 30 mg, 90 mg a day is a more effective dose in reducing platelet and plasma lipid peroxidation parameters. One may suggest that addition of ubinon-9 into the routine treatment regimen allows the therapy for acute ischemic heart disease to be optimize.